# DBV Technologies S.A.: Form 10-Q for the period ended Sep 30, 2021

- Company: [DBV Technologies S.A.](/companies/dbvt.md) (CIK 1613780)
- Form: 10-Q
- Filed: 2021-10-26
- Accepted by EDGAR: Oct 26, 2021, 16:28 ET
- Period: 2021-09-30
- Accession: 0001193125-21-308003
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1613780/000119312521308003/d220478d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1613780/000119312521308003/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-07-01 to 2021-09-30 | $1.3m | us-gaap:Revenues |
| Revenue | 9 months, 2021-01-01 to 2021-09-30 | $2.8m | us-gaap:Revenues |
| Research and development | 3 months, 2021-07-01 to 2021-09-30 | $16.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2021-01-01 to 2021-09-30 | $58.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2021-07-01 to 2021-09-30 | −$24.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2021-01-01 to 2021-09-30 | −$85.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 9 months, 2021-01-01 to 2021-09-30 | −$404.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-07-01 to 2021-09-30 | −$24.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2021-01-01 to 2021-09-30 | −$84.1m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months, 2021-01-01 to 2021-09-30 | −$89.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2021-09-30 | $98.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-09-30 | $110.1m | us-gaap:AssetsCurrent |
| Total assets | at 2021-09-30 | $170.9m | us-gaap:Assets |
| Current liabilities | at 2021-09-30 | $33.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-09-30 | $54.0m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-09-30 | $116.9m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 34,614 characters.

*You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part 1, Item 1 of this Report and with our audited financial statements and related notes thereto for the year ended December 31, 2020, included in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on March 17, 2021, or the Annual Report. This discussion and other parts of this Report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause such differences are discussed in the section of this Report titled “Special Note Regarding Forward-Looking Statements” and under “Item 1A. Risk Factors” in the Annual Report.*

### Overview

We are a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy, or EPITTM, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. We have generated significant data demonstrating that Viaskin’s mechanism of action is novel and differentiated, as it targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. We are advancing this unique technology to treat patients, including infants and children, suffering from food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock.

#### Viaskin Peanut in the United States

In January 2021, we received written responses from the FDA to questions provided in the Type A meeting request, we submitted in October 2020 following the CRL. In exchanges with the FDA, we proposed potential resolutions to two main concerns identified by the FDA in the CRL: the impact of patch adhesion and the need for patch modifications. The FDA agreed with our position that a modified Viaskin Peanut patch should not be considered as a new product entity provided the occlusion chamber of the current Viaskin Peanut patch and the peanut protein dose of 250 µg (approximately 1/1000 of a peanut) remains unchanged and performs in the same way it has performed previously. In order to confirm the consistency of efficacy data between the existing and modified patches, the FDA has requested an assessment comparing the uptake of allergen (peanut protein) between the patches in peanut allergic children ages 4 to 11 years. The FDA also recommended conducting a 6-month, well-controlled safety and adhesion trial to assess the modified Viaskin Peanut patch in the intended patient population.

In the second quarter of 2021, we completed CHAMP (Comparison of adHesion Among Modified Patches), a trial in healthy adult volunteers to evaluate the adhesion of five modified Viaskin Peanut patches in order to identify the top performers. Based on the adhesion parameters studied, we were pleased to learn that all modified Viaskin Peanut patches demonstrated better adhesion performance as compared to the current Viaskin Peanut patch. We then selected two modified patches that performed best out of the five modified patches studied for further development.

The difference between the two selected patches is their shape—one is circular and the other is rectangular with rounded corners. They are both approximately 50% larger than the current patch but maintain the same structure of the occlusion chamber (i.e., foam ring and backing). We also conducted advisory boards with patient caregivers and key opinion leaders to obtain qualitative feedback on the consumer experience with both patches.

In the second quarter of 2021, we initiated PREQUAL, a Phase 1 study in healthy adult volunteers to optimize the allergen sample collection methodologies and validate the assays we intend to use in EQUAL (EQuivalence in Uptake of ALergen) to demonstrate the protein uptake comparability of the modified patch (mVP) to the reference or current patch (cVP).

We submitted the protocol for STAMP (Safety, Tolerability and Adhesion of Modified Patches), the 6-month adhesion and safety study of the modified patch, to the FDA on May 6, and received feedback from the FDA on October 14, 2021. The FDA has requested us a stepwise approach to our modified Viaskin Peanut (mVP) development program. The FDA would like us to review the data from our protein uptake release study prior to providing additional comments on the STAMP protocol design. In its communication, the FDA stated that guidance is forthcoming on how best to demonstrate the protein uptake comparability of the mVP to the reference or current patch (cVP). The STAMP trial will not be initiated until we receive complete feedback from the FDA.

#### Viaskin Peanut in Europe

During the first quarter of 2021, we received the first set of questions from the European Medicines Agency, or EMA, regarding the Marketing Authorization Application, or MAA, for Viaskin Peanut as a treatment for peanut allergy in children ages 4-11. The questions were consistent with our expectations and prefiling conversations with the EMA. We did not receive questions about the impact of adhesion on efficacy. The EMA’s Committee for Medicinal Products for Human Use will provide a recommendation to the European Commission, or EC, on whether to grant a marketing authorization when its review of the Viaskin Peanut MAA is complete.

In July 2021, we received from the EMA a Day 180 list of outstanding issues. The review of the Viaskin Peanut MAA is progressing according to established EMA processes and ongoing conversations with the EMA.

Many of EMA’s Objections and Major Objections have been answered; one Major Objection remained.

We are preparing our responses to the Day 180 letter and evaluating how to best address the Objections, including the remaining Major Objection which questions the limitations of the data, for example, the clinical relevance and effect size supported by a single pivotal study. Further exchanges with EMA are anticipated. We estimate the EMA could issue its decision on potential marketing authorization for Viaskin Peanut in the first quarter of 2022.

### Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the revenue, costs and expenses recognized during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no new policies or significant changes to our critical accounting policies as disclosed in the critical accounting policies described in the Annual Report. Our significant accounting policies are more fully described in Note 1 of the Notes to the Condensed Consolidated Financial Statements in Part I, Item 1 of our Annual Report.

### Results of Operations

#### Comparison of the Three Months Ended September 30, 2021 and 2020

The following table summarizes our results of operations, derived from our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP and presented in thousands of U.S. Dollars, for the three months ended September 30, 2021 and 2020.

|  | Three months ended September 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| **Operating income** | **$1,323** | **$4,158** | **$(2,836)** | **(68%)** |
| **Operating expenses** |  |  |  |  |
| Research and development expenses | (16,320) | (25,751) | 9,430 | (37%) |
| Sales and marketing expenses | (1,072) | (1,595) | 524 | (33%) |
| General and administrative expenses | (8,299) | (6,863) | (1,437) | 21% |
| Restructuring expenses | — | 286 | (286) | 100% |
| **Total Operating expenses** | (25,691) | (33,923) | 8,232 | (24%) |
| Financial income (expense) | 336 | (1,184) | 1,519 | (128%) |
| Income tax | — | (7) | 7 | (100%) |
| **Net loss** | **$(24,033)** | **$(30,955)** | **$6,922** | **(22%)** |

21

#### Operating Income

The following table summarizes our operating income during the three months ended September 30, 2021 and 2020:

|  | Three months ended September 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| Sales | — | — | — | — |
| Other income | 1,323 | 4,158 | (2,836) | (68%) |
| Research tax credit | 1,647 | 1,815 | (168) | (9%) |
| Other operating (loss) income | (324) | 2,344 | (2,668) | (114%) |
| **Total operating income** | **1,323** | **4,158** | **(2,836)** | **(68%)** |

Our operating income is primarily generated from the French research tax credit (*Crédit d’Iimpôt Recherche, or CIR*), and by the revenue recognized under our collaboration agreement with Nestlé Health Science. We generated operating income of $1.3 million during the three months ended September 30, 2021 compared to $4.2 million during the three months ended September 30, 2020. The decrease in operating income is primarily attributable to the change in the revenue recognized under the Nestlé’s collaboration agreement, as we updated the measurement of progress of the Phase II clinical trial conducted as part of the agreement due to delays in new patient enrollment. The decrease in research tax credit is attributable to the decline of eligible expenses in connection with the decrease in Research and development expenses.

#### Research and Development Expenses

The following table summarizes our research and development expenses incurred during the three months ended September 30, 2021 and 2020:

| Research and development expenses | Three Months Ended September 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| External clinical-related expenses | 8,633 | 5,175 | 3,458 | 67% |
| Employee-related costs | 3,228 | 5,876 | (2,648) | (45%) |
| Share-based payment expenses | 933 | 108 | 825 | \* |
| Depreciation, amortization and other costs | 3,526 | 14,592 | (11,066) | (76%) |
| **Total Research and development expenses** | **16,320** | **25,751** | **(9,430)** | **(37%)** |

\*Percentage not meaningful

Research and development expenses decreased by $9.4 million for the three months ended September 30, 2021 compared to the three months ended September 30, 2020, primarily due to a decrease in depreciation, amortization and other costs, as well as in employee-related costs, partially offset by an increase in external clinical-related expenses.

The decrease in depreciation, amortization and other costs was primarily due to the decrease in inventory depreciation, as we wrote down any inventories and work in progress to zero pending regulatory approval in the third quarter of 2020 following the CRL received from the FDA.This variation was partially offset by the accrual recorded in the amount of the difference between our current best estimates of costs yet to be incurred and revenues yet to be recognized for the completion of the Phase II clinical trial conducted as part of the Nestlé agreement.

Employee-related costs, excluding share-based payment expenses, decreased by $2.6 million for the three months ended September 30, 2021, compared to the three months ended September 30, 2020, due to the workforce reduction we implemented as part of our 2020 global restructuring plan.

External clinical-related expenses increased by $3.5 million for the three months ended September 30, 2021, compared to the three months ended September 30, 2020, primarily due to the completion of CHAMP, the initiation of PREQUAL and the preparation of the clinical protocol for STAMP.

The share-based payment expenses recognized for the three months ended September 30, 2020 was triggered by the reversal of share-based payment expenses due to employees’ departures in the context of our restructuring plan.

#### Sales and Marketing expenses

The following table summarizes our sales and marketing expenses incurred during the three months ended September 30, 2021 and 2020:

| Sales and Marketing expenses | Three Months Ended September 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| External professional services | 379 | (239) | 619 | (258%) |
| Employee-related costs | 405 | 2,336 | (1,931) | (83%) |
| Share-based payment expenses (income) | 87 | (182) | 269 | (148%) |
| Depreciation, amortization and other costs | 200 | (320) | 520 | (163%) |
| **Total Sales and Marketing expenses** | **1,072** | **1,595** | **(524)** | **(33%)** |

Sales and marketing expenses amounted to $1.1 million for the three months ended September 30, 2021, compared to $1.6 million for the three months ended September 30, 2020. This decrease was primarily related to a decrease in employee-related costs of $1.9 million due related to the workforce reduction implemented as part of our restructuring plan.

#### General and Administrative expenses

The following table summarizes our general and administrative expenses incurred during the three months ended September 30, 2021 and 2020:

| General and Administrative expenses | Three Months Ended September 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| External professional services | 2,216 | 1,663 | 552 | 33% |
| Employee-related costs | 2,052 | 1,571 | 482 | 31% |
| Share-based payment expenses | 530 | — | 531 | \* |
| Depreciation, amortization and other costs | 3,501 | 3,629 | (128) | (4%) |
| **Total General and Administrative expenses** | **8,299** | **6,863** | **1,437** | **21%** |

\*Percentage not meaningful

General and administrative expenses increased by $1.4 million for the three months ended September 30, 2021 compared to the three months ended September 30, 2020 primarily due to the effect of exchange rates on external professional fees and employee-related costs.

The share-based payment expense was nil for the three months ended September 30, 2020 mostly due to employees’ departures in the context of our 2020 global restructuring plan.

#### Restructuring expenses

We initiated a global restructuring plan in June 2020 to provide operational latitude to progress in the clinical development and regulatory review of investigational Viaskin™ Peanut in the United States and European Union. For the three months ended September 30, 2021, our average headcount was 94, compared to 248 for the three months ended September 30, 2020.

As of September 30, 2021, we had 92 employees. We expect full implementation of the organization-wide cost reduction measures to be completed in the fourth quarter of 2021.

The restructuring costs were mainly comprised of payroll expenses, restructuring-related consulting and legal fees, as well as impairment of facilities and right-of-use assets following resizing of facilities.

There were no restructuring costs for three months ended September 30, 2021.

#### Financial income (expense)

Our financial income was $0.3 million for the three months ended September 30, 2021 compared to a financial expense of $1.2 million for the three months ended September 30, 2020. This item mainly includes foreign exchange income and expenses.

#### Income tax

We did not have any income tax profit for the three months ended September 30, 2021 or 2020.

#### Net loss

Net loss was $24.0 million for the three months ended September 30, 2021, compared to $31.0 million for the three months ended September 30, 2020. Net loss per share (based on the weighted average number of shares outstanding over the period) was $0.44 and $0.56 for the three months ended September 30, 2021 and 2020, respectively.

### Results of Operations

#### Comparison of the Nine Months Ended September 30, 2021 and 2020

The following table summarizes our results of operations, derived from our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP and presented in thousands of U.S. Dollars, for the nine months ended September 30, 2021 and 2020.

|  | Nine months ended September 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| **Operating income** | **$2,776** | **$12,488** | **$(9,713)** | **(78%)** |
| **Operating expenses** |  |  |  |  |
| Research and development expenses | (58,663) | (75,214) | 16,551 | (22%) |
| Sales and marketing expenses | (2,999) | (8,114) | 5,115 | (63%) |
| General and administrative expenses | (26,250) | (26,838) | 587 | (2%) |
| Restructuring expenses | — | (21,003) | 21,003 | (100%) |
| **Total Operating expenses** | **(87,912)** | **(131,169)** | **43,257** | (33%) |
| Financial income (expense) | 597 | (1,380) | 1,977 | (143%) |
| Income tax | 404 | (10) | 414 | \* |
| **Net loss** | **$(84,136)** | **$(120,071)** | **$35,935** | **(30%)** |

\* Percentage not meaningful

#### Operating Income

The following table summarizes our operating income during the nine months ended September 30, 2021 and 2020:

|  | Nine Months ended September 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| Sales | — | — |  |  |
| Other income | 2,776 | 12,488 | (9,713) | (78%) |
| Research tax credit | 5,324 | 7,615 | (2,291) | (30%) |
| Other operating (loss) income | (2,549) | 4,873 | (7,422) | (152%) |
| **Total operating income** | **2,776** | **12,488** | **(9,713)** | **(78%)** |

24

Our operating income was primarily generated from the French research tax credit (*CIR*) and from revenue recognized under our collaboration agreement with Nestlé Health Science. We generated operating income of $2.8 million during the nine months ended September 30, 2021, compared to $12.5 million during the nine months ended September 30, 2020. The decrease in operating income is primarily attributable to the change in the revenue recognized under the Nestlé’s collaboration agreement, as we updated the measurement of progress of the Phase II clinical trial conducted as part of the agreement due to delays in new patient enrollment. The decrease in research tax credit is attributable to the decline in eligible expenses in connection with research and development expenses.

#### Research and Development Expenses

The following table summarizes our research and development expenses incurred during the nine months ended September 30, 2021 and 2020:

| Research and development expenses | Nine Months Ended September 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| External clinical-related expenses | 31,319 | 34,494 | (3,175) | (9%) |
| Employee-related costs | 10,525 | 18,810 | (8,284) | (44%) |
| Share-based payment expenses (income) | 1,747 | (516) | 2,263 | (439%) |
| Depreciation, amortization and other costs | 15,072 | 22,427 | (7,355) | (33%) |
| **Total Research and development expenses** | **58,663** | **75,214** | **(16,551)** | **(22%)** |

Research and development expenses decreased by $16.6 million for the nine months ended September 30, 2021, compared to the nine months ended September 30, 2020, primarily due to a decrease in employee-related costs and depreciation, amortization and other costs, as well as in external clinical-related expenses, offset by an increase in share-based payment expenses.

External clinical-related expenses decreased by $3.2 million for the nine months ended September 30, 2021, compared to the nine months ended September 30, 2020, primarily due to cost containment measures following our 2020 global restructuring plan.

Employee-related costs, excluding share-based payment expenses, decreased by $8.3 million for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020 due to the workforce reduction we implemented as part of our 2020 global restructuring plan.

The decrease in depreciation, amortization and other costs was primarily due to the decrease in inventory depreciation, as we wrote down any inventories and work in progress to zero pending regulatory approval in the third quarter of 2020 following the CRL received from the FDA.This variation was partially offset by the accrual recorded in the amount of the difference between our current best estimates of costs yet to be incurred and revenues yet to be recognized for the completion of the Phase II clinical trial conducted as part of the Nestlé agreement.

The share-based payment income recognized for the nine months ended September 30, 2020 was triggered by the reversal of share-based payment expenses due to employees’ departures in the context of our restructuring plan.

#### Sales and Marketing expenses

The following table summarizes our sales and marketing expenses incurred during the nine months ended September 30, 2021 and 2020:

| Sales and Marketing expenses | Nine Months Ended September 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| External professional services | 771 | 2,881 | (2,111) | (73%) |
| Employee-related costs | 1,282 | 7,038 | (5,757) | (82%) |
| Share-based payment expenses (income) | 246 | (2,052) | 2,298 | (112%) |
| Depreciation, amortization and other costs | 700 | 246 | 454 | 185% |
| **Total Sales and Marketing expenses** | **2,999** | **8,114** | **(5,115)** | **(63%)** |

25

Sales and marketing expenses decreased by $5.1 million for the nine months ended September 30, 2021, compared to the nine months ended September 30, 2020, primarily due to a decrease in employee-related costs and external professional services, partially offset by share-based payment expenses.

Employee-related costs, excluding share-based payments expenses, decreased by $5.8 million for the nine months ended September 30, 2021, compared to the nine months ended September 30, 2020 due to the workforce reduction we implemented as part of our 2020 global restructuring plan.

External professional services decreased by $2.1 million for the nine months ended September 30, 2021, compared to the nine months ended September 30, 2020, primarily as a result of budget discipline measures. The share-based payment expense recognized for the nine months ended September 30, 2021 and the income recognized for the nine months ended September 30, 2020 was triggered by the reversal of share-based payment expenses due to employees’ departures in the context of our restructuring plan.

#### General and Administrative expenses

The following table summarizes our general and administrative expenses incurred during the nine months ended September 30, 2021 and 2020:

| General and Administrative expenses | Nine Months Ended September 30, 2021 | 2020 | $ change | % change |
| --- | ---: | ---: | ---: | ---: |
| External professional services | 6,425 | 10,517 | (4,092) | (39%) |
| Employee-related costs | 7,263 | 7,026 | 237 | 3% |
| Share-based payment expenses (income) | 2,084 | (397) | 2,482 | 625% |
| Depreciation, amortization and other costs | 10,478 | 9,693 | 785 | 8% |
| **Total General and Administrative expenses** | **26,250** | **26,838** | **(587)** | **(2%)** |

\* Percentage not meaningful

General and administrative expenses decreased by $0.6 million for the nine months ended September 30, 2021 compared to the nine months ended September 30, 2020, primarily due to cost containment measures and decreased external professional fees, partially offset by an increase in share-based payment expenses.

The share-based payment expense recognized for the nine months ended September 30, 2021 and the income recognized for the nine months ended September 30, 2020 was triggered by the reversal of share-based payment expense due to employees’ departures in the context of our 2020 global restructuring plan.

#### Restructuring expenses

We initiated a global restructuring plan in June 2020 to provide operational latitude to progress the clinical development and regulatory review of investigational Viaskin™ Peanut in the United States and European Union. For the nine months ended September 30, 2021, our average headcount was 105 compared to 291 for the nine months ended September 30, 2020.

As of September 30, 2021, we had 92 employees. We expect full implementation of the organization-wide costs reduction measures to be completed in the fourth quarter of 2021.

The restructuring costs were mainly comprised of payroll expenses, restructuring-related consulting and legal fees, as well as impairment of facilities and right-of-use assets following resizing of facilities.

There were no restructuring costs for nine months ended September 30, 2021.

#### Financial income (expense)

Our financial income was $0.6 million for the nine months ended September 30, 2021 compared to a financial expense of $1.4 million for the nine months ended September 30, 2020. This item mainly includes foreign exchange income and expenses.

#### Income tax

Our income tax profit was $0.4 million for the nine months ended September 30, 2021. This income tax profit mainly resulted from US tax refunds. We did not have any income tax profit for the nine months ended September 30, 2020.

#### Net loss

Net loss was $84.1 million for the nine months ended September 30, 2021, compared to $120.1 million for the nine months ended September 30, 2020. Net loss per share (based on the weighted average number of shares outstanding over the period) was $1.53 and $2.23 for the nine months ended September 30, 2021 and 2020, respectively.

### Liquidity and Capital Resources

The table below summarizes our sources and uses of cash for the nine months ended September 30, 2021 and 2020.

*(Amounts in thousands of U.S. Dollars)*

|  | Nine Months ended September 30, 2021 | 2020 | $ change | % of change |
| --- | ---: | ---: | ---: | ---: |
| Net cash flow used in operating activities | (89,452) | (132,076) | 42,624 | (32%) |
| Net cash flow provided by (used in) investing activities | 41 | (2,232) | 2,273 | (102%) |
| Net cash flow (used in) provided by financing activities | (103) | 149,624 | (149,726) | (100%) |
| Effect of exchange rate changes on cash and cash equivalents | (8,643) | 12,834 | (21,477) | (167%) |
| **Net (decrease) increase in cash and cash equivalents** | **(98,157)** | **28,150** | **(126,307)** | **(449%)** |

### Operating Activities

Our net cash flows used in operating activities were $89.5 million and $132.1 million during the nine months ended September 30, 2021 and 2020, respectively. Our net cash flows used in operating activities decreased by $42.6 million, or 32%, mainly due to cost containment measures and the decrease in personnel expenses related to the workforce reduction as part of our global restructuring plan. Cash flows used in operating activities for the nine months ended September 30, 2021 includes restructuring costs paid for $7.0 million.

### Investing Activities

Our net cash flows provided by investing activities were $41,000 during the nine months ended September 30, 2021 and net cash flows used in investing activities were $2.2 million during the nine months ended September 30, 2020, respectively. Those investments were mainly for our industrial machinery and equipment, which are commissioned in order to support the commercialization of Viaskin Peanut, if approved.

### Financing Activities

Our net cash flows used in financing activities were $103,000 during the nine months ended September 30, 2021 and net cash flows provided by financing activities were $149.6 million during the nine months ended September 30, 2020. Financing activities consisted mainly of our underwritten global offering in the first quarter of 2020.

#### Cash and Funding Sources

On September 30, 2021, we had $98.2 million in cash and cash equivalents compared to $221.4 million and $196.4 million of cash and cash equivalents on September 30, 2020 and December 31, 2020, respectively. We have incurred net losses and negative cash flows from operations in each year since our inception. Substantially all of our net losses resulted from costs incurred in connection with our development programs and from general and administrative expenses associated with our operations. Net cash used for operating activities was $89.5 million and $132.1 million, respectively, for the nine months ended September 30, 2021 and 2020. For the nine months ended September 30, 2021, we recorded a net loss of $84.1 million.

Since our inception, we have primarily funded our operations with equity financings, and, to a lesser extent, public assistance aimed at supporting innovation and payments associated with French administration on research tax credits (Credit Impot Recherche). We do not generate product revenue and continue to prepare for the potential launch of our first product in the United States and in the European Union, if approved.

During the nine months ended September 2021 and 2020, we obtained the following financing on the public markets by issuance of securities, net of commissions and estimated offering expenses:

*(Amounts in thousands of U.S. Dollars)*

|  | Equity capital |
| --- | ---: |
| Nine months ended September 30, 2020 | $150,010 |
| Nine months ended September 30, 2021 | — |
| **Total** | $150,010 |

28

We have not incurred any bank debt.

Based on our current assumptions, we expect that our current cash and cash equivalents will support our operations into the third quarter of 2022.

### Capital Expenditures

As all the clinical research and development expenditures are expensed until marketing authorizations are obtained, the principal investments made over the nine months ended September 30, 2021 and 2020 have been related primarily to the industrial machinery and equipment, which are expected to be commissioned in order to support the commercialization of Viaskin Peanut, if approved and, secondarily, to the acquisition of computer and office equipment.

### Funding Requirements

Following receipt of a CRL from the FDA in connection with our BLA for Viaskin Peanut, beginning in August 2020, we scaled down our other clinical programs and pre-clinical spend to focus on Viaskin Peanut. We also initiated a global restructuring plan in June 2020 to provide operational latitude to progress the clinical development and regulatory review of Viaskin Peanut in the United States and European Union.

Based on our plans to address the guidance received from the FDA in January 2021 and additional feedback received in October 2021 regarding the protocol for STAMP, and our expected cost savings from implementation of the global restructuring plan, we expect that our current balance of cash and cash equivalents of $98.2 million as of September 30, 2021 will be sufficient to fund our operations into the third quarter of 2022. As of the date of the filing, our available cash is not projected to be sufficient to support our operating plan for the next 12 months. As such, there is substantial doubt regarding the Company’s ability to continue as a going concern.

We intend to seek additional capital as we prepare for the launch of Viaskin Peanut, if approved, and continue other research and development efforts. We may seek to finance our future cash needs through a combination of public or private equity or debt financings, collaborations, license and development agreements and other forms of non-dilutive financings. On June 30, 2021, we filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission, or SEC, utilizing a shelf registration process. Under this shelf registration process, we may offer our ordinary shares, ordinary shares in the form of ADSs or any combination thereof from time to time in one or more offerings up to a total aggregate offering price of $250,000,000.

We cannot guarantee that we will be able to obtain the necessary financing to meet our needs or to obtain funds at attractive terms and conditions, including as a result of disruptions to the global financial markets due to the ongoing COVID-19 pandemic. The ongoing COVID-19 pandemic has already caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks for us, including reduced ability to raise additional capital when needed and on acceptable terms, if at all.

### Contractual Obligations and Other Commitments

There have been no material changes in our contractual obligations and commitments from those disclosed in the Annual Report.

### Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements and do not have variable interests in variable interest entities.

### Smaller Reporting Company Status

We are a smaller reporting company as defined in the Exchange Act. We may, and intend to, take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as we are a smaller reporting company. We may be a smaller reporting company in any year in which (i) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) (a) our annual revenue is less than $100.0 million during the most recently completed fiscal year and (b) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.

## Controls and procedures

As filed, 2,836 characters.

### Disclosure Controls and Procedures

Based on its evaluation as of September 30, 2021, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) were effective to provide reasonable assurance that (i) the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Limitation on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and

procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error of fraud may occur and not be detected.

Filed Oct 26, 2021.
Source: SEC EDGAR, the filing index for accession 0001193125-21-308003. Last ingested by Listed: Nov 14, 2026, 12:53 ET. No prices; not investment advice.
